Results 31 to 40 of about 132,795 (279)
Preferred antiretroviral drugs for the next decade of scale up [PDF]
, 2012 Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission.
Andrieux-Meyer, Isabelle +10 more
core +4 more sources
Advanced NanoBiomed Research, 2022 Herein, lipid‐coated mesoporous silica nanoparticles (LMSNs) are investigated as biomimetic delivery vehicle for two antiretroviral (ARV) compounds, rilpivirine (RPV), and cabotegravir (CAB).
Han Zang +5 more
doaj +1 more source
Drug Interactions and Antiretroviral Drug Monitoring [PDF]
Current HIV/AIDS Reports, 2014 Owing to the improved longevity afforded by combination antiretroviral therapy (cART), HIV-infected individuals are developing several non-AIDS-related comorbid conditions. Consequently, medical management of the HIV-infected population is increasingly complex, with a growing list of potential drug-drug interactions (DDIs). This article reviews some of
Matthew, Foy +3 more
openaire +2 more sources
Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. [PDF]
, 2017 BackgroundThere is ongoing controversy regarding abacavir use in the treatment of HIV infection and the risk of subsequent development of cardiovascular disease.
Baxi, Sanjiv M +3 more
core +3 more sources
BMC Health Services Research, 2012 Background Identification of the determinants of access to investigational drugs is important to promote equity and scientific validity in clinical research.
Girardi Enrico +11 more
doaj +1 more source
Drug resistance and antiretroviral drug development [PDF]
Journal of Antimicrobial Chemotherapy, 2005 As more drugs for treating HIV have become available, drug resistance profiles within antiretroviral drug classes have become increasingly important for researchers developing new drugs and for clinicians integrating new drugs into their clinical practice. In vitro passage experiments and comprehensive phenotypic susceptibility testing are used for the
Robert W, Shafer, Jonathan M, Schapiro
openaire +2 more sources
Interventions for neurocognitive dysfunction [PDF]
, 2017 Purpose of review: To evaluate current barriers to HIV cure strategies and interventions for neurocognitive dysfunction with a particular focus on recent advancements over the last three years. Recent findings: Optimal anti-retroviral therapy (ART) poses
Brew, B, Ellero, J, Lubomski, M
core +2 more sources
Pharmacokinetics of antiretroviral drugs in infancy
Southern African Journal of HIV Medicine, 2009 Infancy (from birth until 1 year of age) is a time of rapid changes within the body of a child. These changes affect pharmacokinetics in many ways. The CHER study1 showed that early antiretroviral treatment reduces mortality and disease progression ...
Helen McIlleron, Hermien Gous
doaj +1 more source
Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study [PDF]
, 2014 Background: Atazanavir and lopinavir represent the main HIV protease inhibitors recommended in pregnancy, but comparative data in pregnant women are limited. Methods: Women from a national observational study, exposed in pregnancy to either atazanavir or
. . . ]. +17 more
core +1 more source
Jurnal Ilmiah KesehatanHuman Immunodeficiency Virus (HIV) attacks white blood cells, leading to a weakened immune system. Acquired Immune Deficiency Syndrome (AIDS) refers to the set of symptoms caused by the decline in immunity due to HIV.
Riska Putri Dessyanti +2 more
doaj +1 more source